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Objectives. This review summarizes the results of single-photon
emission computed tomographic (SPECT) technetium-99m (Tc-
99m) tracer imaging in patients with stable symptoms, patients
with acute coronary syndromes, patients undergoing major non-
cardiac surgery and patients with chest pain in the emergency
department.
Background. Previous studies have examined the prognostic
value of stress thallium imaging in several subsets of patients with
ischemic heart disease. At present, >50% of myocardial perfusion
studies are performed with technetium-labeled tracers in the
United States. Furthermore, there is a shift from diagnostic to the
prognostic utility of stress testing. There are important differences
between technetium-labeled tracers and thallium-201. It is there-
fore important to review the prognostic value of technetium-
labeled tracers.
Methods. We analyzed published reports in English on risk
assessment using Tc-99m perfusion tracers.
Results. The largest experience is in patients with stable
symptoms, comprising >12,000 patients in 14 studies. In these
patients, normal stress SPECT sestamibi images were associated
with an average annual hard event rate of 0.6% (death or nonfatal
myocardial infarction [MI]). In contrast, patients with abnormal
images had a 12-fold higher event rate (7.4% annually). Both fixed
and reversible defects are prognostically important, and quanti-
tative analysis shows increased risk in relation to the severity of
the abnormality. These results are similar to those obtained with
thallium-201.
Conclusions. Patients with stable chest pain syndromes and
normal stress SPECT sestamibi images have a very low risk of
death or nonfatal MI. It is highly unlikely that coronary revascu-
larization can improve survival in such patients. Patients with
abnormal images have an intermediate to high risk for future
cardiac events, depending on the degree of the abnormality.
Further prospective studies comparing aggressive medical ther-
apy with coronary revascularization in these patients are war-
ranted.
(J Am Coll Cardiol 1998;32:57–62)
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The Food and Drug Administration approved the clinical use
of technetium-99m (Tc-99m) sestamibi for myocardial perfu-
sion imaging in 1991 and Tc-99m tetrofosmin in 1996 (1). In
1996, technetium tracers were used in ;59% of the 4.9 million
studies performed, either alone or in combination with
thallium-201 (Tl-201) (dual-isotope imaging) (Technology
Marketing Group).
As with thallium, there has been a gradual shift from
diagnostic to prognostic applications of technetium tracers.
This shift occurred at a time when the prognostic value of
stress thallium imaging had been well established in many
subsets of patients with coronary artery disease (CAD). For
example, patients with normal stress thallium images have
been shown to have a benign outcome, with a ,1% hard event
rate/year (death or nonfatal myocardial infarction (MI) (1).
Patients with abnormal images, including those with fixed
defects, reversible defects, increased lung thallium uptake, left
ventricular (LV) dilation, multivessel abnormalities and large
perfusion abnormalities, are at higher risk; the risk increases in
proportion to the degree of the abnormality (1–13).
There are obviously many important differences between
Tl-201 and technetium tracers, among which are the lower
extraction of the technetium tracers and the ambiguity of the
implications of the lung tracer uptake. Nevertheless, several
studies, including multicenter studies, showed that the diag-
nostic accuracy of technetium tracers is comparable to that of
Tl-201 (1). This comparability, but not superiority (despite
superior imaging characteristics), has been a matter of contro-
versy and has been attributed to many factors, including but
not limited to referral bias and observer experience. However,
diagnostic accuracy is a moving target, and the recent intro-
duction of gating, which allows simultaneous assessment of
perfusion and function as well as the ability to perform
attenuation, scatter and depth resolution compensation, has
literally made the earlier results obsolete (14,15).
It is nevertheless important to examine the prognostic value
of technetium-labeled tracers, and because of the longer
duration of the use of sestamibi, the latter will be the subject of
this review, which includes an analysis of published reports in
English in patients with stable symptoms, patients with acute
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coronary syndromes, patients undergoing major noncardiac
surgery and patients with chest pain in the emergency depart-
ment. All studies were performed with single-photon emission
computed tomography (SPECT) but without gating or atten-
uation correction.
Patients With Stable Chest Pain Syndromes
A summary of the studies dealing with patients with stable
chest pain syndromes is presented in Table 1 (16–29). The
stress modalities included exercise in eight studies and phar-
macologic modalities in six. In three studies from the same
institution (16,19,20), a dual-isotope protocol (rest thallium
and stress sestamibi) was used, but because the prognostic
value was related to the stress images, these studies were
included here. Four of the 14 studies were from the same
institution; 3 of these 4 studies used exercise and 1 pharmaco-
logic testing. It is conceivable that the largest study (20) also
included patients described in earlier, smaller studies (16,23).
Cumulatively, there were .12,000 patients in these studies;
55% of patients were men, and the mean age of the patients
was 61 years. Traditional coronary risk factors were present in
many patients, such as remote MI in 22%, hypertension in 50%
and diabetes mellitus in 16%. The average follow-up period
was 20 months.
The annual rate of hard cardiac events (death or nonfatal
MI) in patients with normal stress SPECT sestamibi images
and in those with abnormal images is shown in Table 1. The
average annual event rate was 12-fold higher in patients with
abnormal images than in patients with normal images (7.4% vs.
0.6%) (Fig. 1). Therefore, patients with normal stress sestamibi
images had a very low hard event rate of ,1%/year, similar to
the experience with stress thallium imaging. This event rate is
comparable to that in the general population in the United
States (30). In all studies, both fixed and reversible defects
were prognostically important. Fixed defects are a more im-
portant predictor of death whereas reversible defects are an
important predictor of nonfatal MI. Studies that included
quantitative assessment of defect size (16,19,20,23) showed
that the event rate was significantly greater in patients with
severe than in those with mild abnormalities. For example, in
one study (16), the annual hard event rate was 10.6% in
patients with severe and 3.5% in patients with mild abnormal-
ities and in another (19), the annual hard event rate was 6%
and 3%, respectively. Furthermore, the prognostic power of
Abbreviations and Acronyms
CABG 5 coronary artery bypass graft surgery
CAD 5 coronary artery disease
LV 5 left ventricular
LVEF 5 left ventricular ejection fraction
MI 5 myocardial infarction
PTCA 5 percutaneous transluminal coronary angioplasty
SPECT 5 single-photon emission computed tomography (tomographic)
Tc-99m 5 technetium-99m
Tl-201 5 thallium-201
Table 1. Summary of Studies on Risk Assessment Using Stress Single-Photon Emission Computed Tomographic Technetium-99m Sestamibi
Study (ref no.) Year
No. of
Pts
Mean
Age (yr) Men
Hx of
Type of
Stress Tracer
F/U
(mo)
Hard Events*
MI HTN DM NL SPECT AB SPECT
Hachamovitch et al. (16) 1997 1,159 72 50% 18% 55% 66% AD Dual† 275 1.6 7
Boyne et al. (17) 1997 229 58 50% 27% — — Ex Mibi 19 0.8 5.4
Nallamouthu et al. (18) 1996 412 57 65% 6% 43% 11% Ex Mibi 17 0.2 7.8
Hachamovitch et al. (19) 1996 2,113 61 60% 0 39% 9% Ex Dual† 19 0.2 4.7
Hachamovitch et al. (20) 1996 4,136 63 0 21% — — Ex Dual 20 0.4 6
Geleijnse et al. (21) 1996 80 61 0 13% 53% 13% Dob Mibi 23 0 —
Geleijnse et al. (22) 1996 392 60 56% 48% 43% 15% Dob Mibi 22 0.8 9.2
Berman et al. (23) 1995 1,702 62 61% 11% — 10% Ex Mibi 20 0.1 4.5
Heller et al. (24) 1995 512 67 44% 27% 58% 25% DP Mibi 13 1.3 7.4
Zanco et al. (25) 1995 147 53 82% 40% — — Ex Mibi 43 0 8.2
Brown et al. (26) 1994 234 55 54% — — — Ex/DP Mibi 10 0.5 —
Stratmann et al. (27) 1994 521 60 98% 35% 48% 12% Ex Mibi 13 0.5 7
Stratmann et al. (28) 1994 534 65 97% 37% 59% 21% DP Mibi 13 1.8 13.8
Raiker et al. (29) 1994 208 59 52% 5% — — Ex Mibi 14 0.4 —
Total/average 12,360 61 55% 22% 50% 16% — Mibi 20 0.6 7.4
*Death or nonfatal myocardial infarction (MI). †Stress MIBI/rest thallium. AB 5 abnormal; AD 5 adenosine; DM 5 diabetes mellitus; Dob 5 dobutamine; DP 5
dipyridamole; Ex 5 exercise; F/U 5 follow-up; HTN 5 hypertension; Hx 5 history; Mibi 5 sestamibi; NL 5 normal; Pts 5 patients; ref 5 reference; SPECT 5
single-photon emission computed tomography; — 5 not available.
Figure 1. Rate of hard cardiac events (death or nonfatal MI) in
patients with normal and abnormal stress SPECT images.
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normal and abnormal stress images was equally important in
men and women. In fact, women with severe abnormalities had
a worse outcome than men with severe abnormalities (8% vs.
4% [5]). Incorporation of other SPECT variables, such as LV
dilation (transient or fixed), LV ejection fraction (LVEF) and
volumes (derived from gated SPECT), are likely to further
enhance the prognostic power of SPECT imaging but require
further study (7,9,10,15).
Classification of patients into low and high risk has been
confirmed regardless of the pretest probability of CAD; that is,
patients with a high pretest probability of CAD but normal
stress SPECT images have a benign outcome, as do patients
with a low pretest probability of CAD and normal images.
However, because the overall risk in patients with a low pretest
probability of CAD is low, stress imaging in this group is
probably not cost-effective. The most cost-effective strategy is
to study patients with an intermediate to high pretest proba-
bility of CAD (19,20). Furthermore, when quantitative analysis
such as the summed stress score (determined by the extent and
severity of abnormalities on the basis of a 20-segment model)
was used, the risk of death and nonfatal MI varied according to
the severity of abnormalities (19,31). For example, patients
with mild abnormalities had an intermediate risk of nonfatal
MI and a low risk for cardiac death, whereas patients with
severe abnormalities had a high risk for death and an inter-
mediate risk for nonfatal MI. These observations are impor-
tant because coronary revascularization, including percutane-
ous transluminal coronary angioplasty (PTCA) and coronary
artery bypass graft surgery (CABG), have not been shown to
lower the rate of nonfatal MI (32).
In our experience (5), events occurred ;2 years from the
index stress test in patients with normal SPECT images. This
finding may suggest that the “warranty” period for a normal
stress sestamibi scan (i.e., duration of follow-up after a normal
stress study) appears to be ;2 years; after that period, the
event rate increases, probably reflecting the progressive nature
of underlying CAD. However, the value of follow-up periodic
testing in asymptomatic patients is still unclear because of
improvements in medical therapy.
The prognostic value of stress testing with SPECT has also
been confirmed in relation to the Duke treadmill exercise
score. This score, which incorporates exercise duration and ST
segment depression and angina during exercise, has been used
to stratify patients into low, intermediate and high risk groups
(33,34). The intermediate risk group comprised at least 50% of
patients studied in a multicenter study of .4,581 patients (35).
Patients with an intermediate Duke treadmill exercise score
and normal SPECT images (50% of these were done with
sestamibi) had an event rate of only 0.2%/year. American
College of Cardiology/American Heart Association guidelines
reports (36,37) have recommended that patients with an
intermediate Duke score undergo either coronary angiography
or an imaging modality (36,37). It is to be hoped that subse-
quent practice guidelines will carefully consider the new evi-
dence and recommend the use of stress myocardial perfusion
imaging in such patients.
It is equally important to note that the rate of early
catheterization and coronary angiography was very low in
patients with normal images (3.8% [16], 1% [19] and 1.4%
[14]) and appropriately high in patients with abnormal images
(17% [19] and 10% [16] for mild abnormalities, 42% [19] and
27% [16] for severe abnormalities).
Noncardiac Surgery
Several guidelines have been published for risk assessment
of patients undergoing major noncardiac surgery (38–41). This
review is not intended to summarize these guidelines nor to
critique them, but only to provide summary of published
reports on the use of Tc-99m sestamibi. The risk after major
noncardiac surgery includes perioperative and late events. The
perioperative risk is exceedingly low in patients with normal
stress sestamibi images. Similar to that in patients with stable
symptoms, the late event rate is significantly higher in patients
with abnormal than in those with normal scans (Table 2)
(42–44).
Table 2. Summary of Studies on Risk Assessment Using Technetium-99m Sestamibi in Coronary Artery Disease
Study (ref no.)* Year Study
No. of
Pts
Mean
Age (yr) Men
%
Abnormal Scan Type F/U
Events
Type of Events
NL
SPECT
AB
SPECT
Stratmann et al. (49) 1995 UA 128 64 100% 77% DP 16 5% 23% D, MI
Stratmann et al. (48) 1995 UA 126 58 100% 59% Ex 12 2% 14% D, MI
Miller et al. (47) 1995 MI 274 62 77% 26% Rest 12 0 7% D
Travin et al. (46) 1995 MI 120 61 67% 80% Ex 15 5% 30% D, MI, UA
Miller et al. (45) 1994 MI/UA 137 65 92% 80% DP 10 0 22% D, MI
Maunoury et al. (44) 1996 Preop 43 64 47% 35% AD 0.1 0 27% MI, UA
Stratmann et al. (43) 1995 Preop 197 65 98% 56% DP 21 3% 5% D, MI, UA, PE
Stratmann et al. (42) 1996 Preop 229 67 99% 60% DP 0.1 1% 14% D, MI, UA, PE
*References 42 to 44 addressed perioperative evaluation, and references 45 to 49 addressed risk assessment in patients with acute coronary syndromes. AD 5
adenosine; D 5 death; PE 5 pulmonary edema; Preop 5 preoperative evaluation; UA 5 unstable angina; other abbreviations as in Table 1.
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Acute Coronary Syndromes
A limited number of studies in small groups of patients have
evaluated the use of sestamibi imaging either at rest or during
stress in patients with unstable angina or after acute MI. Again,
patients with normal images or small defects have a signifi-
cantly better outcome than patients with abnormal images or
large defects (Table 2) (45–49). Patients with an acute MI may
benefit from simultaneous assessment of myocardial perfusion
and function using gated perfusion imaging because both
LVEF and perfusion defect size are prognostically important.
Preliminary data from a multicenter study of 268 patients
demonstrated (50) that early pharmacologic stress imaging
may be useful for risk stratification in patients admitted with a
diagnosis of acute MI. More studies in larger series of patients
with and without thrombolytic therapy and or angioplasty are
needed.
Patients With Chest Pain in the
Emergency Department
It is estimated that 6 million patients/year visit the emer-
gency department in the United States for evaluation of chest
pain (7% of all visits), and although only 10% to 15% of these
patients have an acute MI, ;50% are admitted to the coronary
care unit to rule out acute MI (51–56). Several studies show
that patients with a low risk rest perfusion scan with Tc-99m
sestamibi in the emergency department have a low subsequent
cardiac event rate, whereas patients with a high risk scan have
a higher probability of acute MI, revascularization or docu-
mentation of stenoses on cardiac catheterization (Table 3)
(56–60).
Conclusions
Several studies show that patients with chest pain syn-
dromes but normal stress SPECT perfusion images using
Tc-labeled tracers have a very low event rate (,1%/year for
death or nonfatal MI). It is therefore very unlikely that further
invasive strategies, including PTCA or CABG, can improve the
outcome. These results are similar to those for stress SPECT
thallium imaging but differ from stress two-dimensional echo-
cardiography. Multiple studies using stress echocardiography
have shown (61) a higher event rate in patients with no
evidence of ischemia. The difference between the prognostic
value of different stress tests underscores the fact that outcome
results by one method cannot be extrapolated to another. The
risk of events is substantially higher in patients with abnormal
than in those with normal SPECT imaging results. The man-
agement of patients with abnormal images as well as the
frequency of testing are not clear and should at present be
individualized; they deserve further study.
We thank Renee Brown for secretarial assistance.
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